Prognostic Relevance of Pretherapeutic Gamma-Glutamyltransferase in Patients with Primary Metastatic Breast Cancer

Gamma-glutamyltransferase (GGT) is a known marker for apoptotic balance and cell detoxification. Recently, an association of baseline GGT levels and breast cancer incidence, tumor progression and chemotherapy resistance was shown. The purpose of this study was to evaluate the association of pre-ther...

Full description

Saved in:
Bibliographic Details
Published in:PloS one Vol. 10; no. 4; p. e0125317
Main Authors: Staudigl, Christine, Concin, Nicole, Grimm, Christoph, Pfeiler, Georg, Nehoda, Regina, Singer, Christian F., Polterauer, Stephan
Format: Journal Article
Language:English
Published: United States Public Library of Science 27.04.2015
Public Library of Science (PLoS)
Subjects:
Aged
Analysis
Apoptosis
Biomarkers - blood
Breast cancer
Breast Neoplasms - pathology
Cancer
Cancer metastasis
Cancer patients
Care and treatment
Chemoresistance
Chemotherapy
Detoxification
Development and progression
Drug Resistance, Neoplasm
ErbB-2 protein
Female
gamma-Glutamyltransferase - blood
Health aspects
Histology
Humans
Medical diagnosis
Medical prognosis
Metastases
Middle Aged
Patients
Prognosis
Retrospective Studies
Risk
Survival
Survival Analysis
Tumors
γ-Glutamyltransferase
ISSN:1932-6203, 1932-6203
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Gamma-glutamyltransferase (GGT) is a known marker for apoptotic balance and cell detoxification. Recently, an association of baseline GGT levels and breast cancer incidence, tumor progression and chemotherapy resistance was shown. The purpose of this study was to evaluate the association of pre-therapeutic GGT levels, clinical-pathological parameters and survival in patients with primary metastatic breast cancer (PMBC). In this multicenter analysis, pre-therapeutic GGT levels and clinical-pathological parameters of 114 patients diagnosed with PMBC between 1996 and 2012 were evaluated. The association between GGT levels and clinical-pathological parameters were analysed. Patients were stratified into four GGT risk-groups (GGT < 18.00 U/L: normal low, 18.00 to 35.99 U/L: normal high, 36.00 to 71.99 U/L: elevated and ≥ 72.00 U/L: highly elevated) and survival analyses were performed. Patients in the high risk GGT group had a poorer overall survival, when compared to the low risk group with five-year overall survival rates of 39.5% and 53.7% (p = 0.04), respectively. Patients with larger breast tumors had a trend towards higher GGT levels (p = 0.053). Pre-therapeutic GGT levels were not associated with indicators of aggressive tumor biology such as HER2-status, triple negative histology, or poorly differentiated cancers. Pre-therapeutic GGT serum level might serve as a novel prognostic factor for overall-survival in patients with PMBC.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
Conceived and designed the experiments: SP CG CFS. Performed the experiments: SP CG CS GP. Analyzed the data: SP CG. Contributed reagents/materials/analysis tools: CS NC RN CFS GP. Wrote the paper: CS SP. Data Collection: CS NC RN.
Competing Interests: The authors have declared that no competing interests exist.
ISSN:1932-6203
1932-6203
DOI:10.1371/journal.pone.0125317